10/18/2007
– Eli Lilly and Company (NYSE:LLY) and
MacroGenics, Inc. announced that the two companies have entered into a global strategic alliance to develop and commercialize
teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases.
As part of the deal, Lilly will acquire the exclusive rights to the molecule. Teplizumab is currently being studied in the PROTÉGÉ trial, a global pivotal Phase II/III clinical trial for individuals with
recent-onset type 1 diabetes*...
MacroGenics' Press Release -
Lilly's Press Release -
